AR108101A1 - Compuestos agonistas de gpr119 y método para tratar enfermedades y afecciones mediado a través de gpr119 - Google Patents
Compuestos agonistas de gpr119 y método para tratar enfermedades y afecciones mediado a través de gpr119Info
- Publication number
- AR108101A1 AR108101A1 ARP170100901A ARP170100901A AR108101A1 AR 108101 A1 AR108101 A1 AR 108101A1 AR P170100901 A ARP170100901 A AR P170100901A AR P170100901 A ARP170100901 A AR P170100901A AR 108101 A1 AR108101 A1 AR 108101A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- gpr119
- formula
- affections
- treat diseases
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Child & Adolescent Psychology (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente se refiere a compuestos de fórmula (1) como agonistas de GPR119, composiciones que contienen dichos compuestos y método de preparación de las mismas. Reivindicación 1: Un compuesto caracterizado porque tiene la fórmula (1), en donde, X¹, X², X³ y X⁴ son cada uno independientemente N, O, S o CH; Y se selecciona a partir de H, OH, halógeno, C₁₋₆ alquilo, C₁₋₆ alcoxi, -(CH)ₙ, amino,-CO, -CONH, -NH(alquilo), -N(alquilo)₂, -NH-aralquilo, -OCH(CH₃); n es 0, 1, 2 ó 3; ⁻ ⁻ ⁻ ⁻ ⁻ es independientemente ya sea un enlace simple o un enlace doble, siempre que enlaces dobles adyacentes (=C=) no estén permitidos; R¹ se selecciona a partir de los restos del grupo de fórmulas (2); R² se selecciona a partir de los restos del grupo de fórmulas (3); R³ se selecciona a partir de H, OH, halógeno, alquilo C₁₋₆, alcoxi C₁₋₆, -(CH)ₙ, amino, -CO, -CONH, -NH(alquilo), -N(alquilo)₂, -NH-aralquilo, -CF₃, -OCH(CH₃), un resto de fórmula (4), un resto de fórmula (5); y sales, hidratos y estereoisómeros farmacéuticamente aceptables de los mismos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201611012425 | 2016-04-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR108101A1 true AR108101A1 (es) | 2018-07-18 |
Family
ID=58794109
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP170100901A AR108101A1 (es) | 2016-04-08 | 2017-04-07 | Compuestos agonistas de gpr119 y método para tratar enfermedades y afecciones mediado a través de gpr119 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US10526345B2 (es) |
| EP (1) | EP3440087B1 (es) |
| JP (1) | JP6831450B2 (es) |
| CN (1) | CN109415381B (es) |
| AR (1) | AR108101A1 (es) |
| AU (2) | AU2017246996B2 (es) |
| CA (1) | CA3020478C (es) |
| ES (1) | ES2926625T3 (es) |
| MX (1) | MX2018012087A (es) |
| NZ (2) | NZ763098A (es) |
| RU (1) | RU2749111C2 (es) |
| TW (1) | TWI657091B (es) |
| WO (1) | WO2017175068A1 (es) |
| ZA (1) | ZA201807350B (es) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3848035A1 (en) | 2015-12-10 | 2021-07-14 | PTC Therapeutics, Inc. | 1,4-disubstituted pyridazine compounds for treating huntington's disease |
| US10208030B2 (en) * | 2016-04-08 | 2019-02-19 | Mankind Pharma Ltd. | GPR119 agonist compounds |
| SG11201911615WA (en) | 2017-06-05 | 2020-01-30 | Ptc Therapeutics Inc | Compounds for treating huntington's disease |
| CA3067592A1 (en) | 2017-06-28 | 2019-01-03 | Ptc Therapeutics, Inc. | Methods for treating huntington's disease |
| CA3067591A1 (en) | 2017-06-28 | 2019-01-03 | Ptc Therapeutics, Inc. | Methods for treating huntington's disease |
| WO2019191092A1 (en) | 2018-03-27 | 2019-10-03 | Ptc Therapeutics, Inc. | Compounds for treating huntington's disease |
| JP7421507B2 (ja) | 2018-06-27 | 2024-01-24 | ピーティーシー セラピューティクス， インコーポレイテッド | ハンチントン病を処置するためのヘテロ環式およびヘテロアリール化合物 |
| CA3104516A1 (en) * | 2018-06-27 | 2020-01-02 | Ptc Therapeutics, Inc. | Heteroaryl compounds for treating huntington's disease |
| WO2020005882A1 (en) | 2018-06-27 | 2020-01-02 | Ptc Therapeutics, Inc. | Heteroaryl compounds for treating huntington's disease |
| WO2020156241A1 (zh) * | 2019-01-31 | 2020-08-06 | 中国医药研究开发中心有限公司 | 芳环或芳杂环类化合物及其制备方法和医药用途 |
| US20230322754A1 (en) * | 2020-04-28 | 2023-10-12 | Kymera Therapeutics, Inc. | Irak inhibitors and uses thereof |
| WO2021226261A1 (en) | 2020-05-06 | 2021-11-11 | Ajax Therapeutics, Inc. | 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors |
| BR112022023359A2 (pt) | 2020-05-19 | 2023-04-18 | Kallyope Inc | Ativadores de ampk |
| EP4172162A1 (en) | 2020-06-26 | 2023-05-03 | Kallyope, Inc. | Ampk activators |
| WO2023009712A1 (en) * | 2021-07-29 | 2023-02-02 | Ajax Therapeutics, Inc. | Heteroaryloxy thiazolo azines as jak2 inhibitors |
| AU2022388555A1 (en) | 2021-11-09 | 2024-05-02 | Ajax Therapeutics, Inc. | 6-he tero aryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1340697A (en) * | 1920-02-24 | 1920-05-18 | Austin Herbert | Road-wheel of the sheet-metal type |
| NZ225967A (en) | 1987-09-02 | 1992-03-26 | Smithkline Beckman Corp | Substituted pyrrolo(1,2-a)imidazole and pyrrolo(1,2-a)pyridine derivatives; pharmaceutical compositions; intermediates |
| JPH11502503A (ja) | 1994-12-21 | 1999-03-02 | ザ ダウ ケミカル カンパニー | 置換チアジアゾール類、それらを含有する組成物並びに抗微生物剤及び海産生物による汚染に対する防止剤としてのそれらの使用 |
| ES2543358T3 (es) | 2008-03-31 | 2015-08-18 | Cymabay Therapeutics, Inc. | Compuestos de arilo de oximetileno y usos de los mismos |
| US20110160222A1 (en) | 2008-11-26 | 2011-06-30 | Metabolex, Inc. | Modulators of glucose homeostasis for the treatment of diabetes and metabolic disorders |
| JP2013525489A (ja) | 2010-05-06 | 2013-06-20 | ブリストル−マイヤーズ スクイブ カンパニー | Ｇｐｒ１１９修飾因子としての二環式ヘテロアリール類似体 |
| UY33805A (es) * | 2010-12-17 | 2012-07-31 | Boehringer Ingelheim Int | ?Derivados de dihidrobenzofuranil-piperidinilo, aza-dihidrobenzofuranilpiperidinilo y diaza-dihidrobenzofuranil-piperidinilo, composiciones farmacéuticas que los contienen y usos de los mismos?. |
| CA2825124A1 (en) | 2011-01-21 | 2012-07-26 | Boehringer Ingelheim International Gmbh | Fused dihydrofurans as gpr119 modulators for the treatment of diabetes, obesity and related disorders |
| KR101668514B1 (ko) * | 2011-02-25 | 2016-10-21 | 머크 샤프 앤드 돔 코포레이션 | 항당뇨병제로서 유용한 신규 시클릭 아자벤즈이미다졸 유도체 |
| EP2718279B1 (en) * | 2011-06-09 | 2016-08-10 | Rhizen Pharmaceuticals SA | Novel compounds as modulators of gpr-119 |
| CN102898400B (zh) | 2011-07-28 | 2015-04-29 | 北京韩美药品有限公司 | Gpr119激动剂及其应用 |
| ES2759010T3 (es) | 2012-06-12 | 2020-05-07 | Chong Kun Dang Pharmaceutical Corp | Derivados de piperidina como agonistas del GPR119 |
-
2017
- 2017-04-04 US US15/478,883 patent/US10526345B2/en active Active
- 2017-04-05 MX MX2018012087A patent/MX2018012087A/es unknown
- 2017-04-05 JP JP2019503800A patent/JP6831450B2/ja active Active
- 2017-04-05 WO PCT/IB2017/000471 patent/WO2017175068A1/en active Application Filing
- 2017-04-05 CA CA3020478A patent/CA3020478C/en active Active
- 2017-04-05 AU AU2017246996A patent/AU2017246996B2/en active Active
- 2017-04-05 NZ NZ763098A patent/NZ763098A/en unknown
- 2017-04-05 NZ NZ746954A patent/NZ746954A/en unknown
- 2017-04-05 EP EP17726352.2A patent/EP3440087B1/en active Active
- 2017-04-05 RU RU2018138050A patent/RU2749111C2/ru active
- 2017-04-05 ES ES17726352T patent/ES2926625T3/es active Active
- 2017-04-05 CN CN201780022556.2A patent/CN109415381B/zh active Active
- 2017-04-07 TW TW106111799A patent/TWI657091B/zh active
- 2017-04-07 AR ARP170100901A patent/AR108101A1/es active IP Right Grant
-
2018
- 2018-11-02 ZA ZA2018/07350A patent/ZA201807350B/en unknown
-
2019
- 2019-10-14 US US16/601,109 patent/US10919915B2/en active Active
-
2020
- 2020-02-27 AU AU2020201450A patent/AU2020201450B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| AU2020201450A1 (en) | 2020-03-19 |
| EP3440087B1 (en) | 2022-08-10 |
| CA3020478A1 (en) | 2017-10-12 |
| NZ746954A (en) | 2020-04-24 |
| BR112018070727A2 (pt) | 2019-03-06 |
| AU2020201450B2 (en) | 2021-07-01 |
| RU2749111C2 (ru) | 2021-06-04 |
| WO2017175068A8 (en) | 2018-05-11 |
| MX2018012087A (es) | 2019-06-12 |
| AU2017246996A1 (en) | 2018-11-01 |
| ES2926625T3 (es) | 2022-10-27 |
| CA3020478C (en) | 2021-07-20 |
| TWI657091B (zh) | 2019-04-21 |
| CN109415381A (zh) | 2019-03-01 |
| AU2017246996B2 (en) | 2019-11-28 |
| JP6831450B2 (ja) | 2021-02-17 |
| US20200040006A1 (en) | 2020-02-06 |
| US10919915B2 (en) | 2021-02-16 |
| NZ763098A (en) | 2023-04-28 |
| US20170291910A1 (en) | 2017-10-12 |
| ZA201807350B (en) | 2019-08-28 |
| EP3440087A1 (en) | 2019-02-13 |
| RU2018138050A3 (es) | 2020-05-12 |
| RU2018138050A (ru) | 2020-05-12 |
| TW201741318A (zh) | 2017-12-01 |
| US10526345B2 (en) | 2020-01-07 |
| JP2019513834A (ja) | 2019-05-30 |
| WO2017175068A1 (en) | 2017-10-12 |
| CN109415381B (zh) | 2022-03-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR108101A1 (es) | Compuestos agonistas de gpr119 y método para tratar enfermedades y afecciones mediado a través de gpr119 | |
| AR108102A1 (es) | Compuestos agonistas de gpr119 y método para tratar enfermedades y afecciones mediado a través de gpr119 | |
| AR093759A1 (es) | Dihidropiridona p1 como inhibidores del factor xia | |
| PE20210667A1 (es) | Derivados de benzamida para la inhibicion de la actividad abl1, abl2 y bcr-abl1 | |
| AR102361A1 (es) | Compuestos de metil-quinolina útiles para inhibir la sintasa-1 de prostaglandina microsomal e2 | |
| GEP20207105B (en) | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors | |
| CU20160097A7 (es) | Compuestos de imidazopirazina como inhibidores de syk | |
| AR095885A1 (es) | Compuestos derivados de arilpirrolopiridina como inhibidores de lrrk2 | |
| AR092270A1 (es) | Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b | |
| AR081058A1 (es) | Derivados de arilmetoxi isoindolina, composiciones que los comprenden y su uso en el tratamiento del cancer. | |
| AR090589A1 (es) | INHIBIDORES DE b-LACTAMASA ISOXAZOL | |
| AR085004A1 (es) | Inhibidores selectivos de glicosidasas y usos de los mismos | |
| UY36207A (es) | Inhibidores de la syk | |
| AR090121A1 (es) | Compuestos de oxazolidin-2-ona y usos de los mismos | |
| CL2021001098A1 (es) | Derivados de quinolina como inhibidores de la integrina alfa4beta7 | |
| CO7280475A2 (es) | Derivados de azaindol que actuan como inhibidores de pi3k | |
| BR112014001083A8 (pt) | composto, processo para a preparação de um composto, composição farmacêutica, método para o tratamento de doenças e uso de um composto | |
| DOP2014000178A (es) | Nuevos derivados de bencil sulfonamida útiles como inhibidores de mogat-2 | |
| AR097963A1 (es) | Antagonistas de receptor ep3 de prostaglandina | |
| EA201591645A1 (ru) | Hантагонисты, имеющие феноксипиперидиновое ядро в структуре | |
| ECSP088257A (es) | Derivados de amida | |
| AR089122A1 (es) | Formulaciones orales para tratar la sobrecarga de metales | |
| PE20140629A1 (es) | Derivados de fenil-isoxazol y procedimiento para la preparacion de los mismos | |
| AR071111A1 (es) | Derivados de amidas del acido 3-trifluorometil-pirazin-2-carboxilico como agentes para aumentar el hdl-colesterol, composiciones farmaceuticas y un metodo para su preparacion. | |
| AR073842A1 (es) | Derivados del acido 4- dimetilaminobutirico , proceso para su preparacion , composiciones farmacéuticas y uso de los mismos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |